The founder, chairman, and chief scientist of Chengdu Zenitar Biomedical Technology Co., Ltd., a 1st-level professor at West China Hospital and a 2nd-level professor at Sichuan University. She was the leader of the innovative and entrepreneurial team introduced by Guangdong Province's "Tumor and Diabetes Research Development" program and the chief scientist of Guangdong Sisheng Pharmaceutical Co., Ltd. (002317.SZ) (2012-2017). A leader of the Tianfu Thousand Talents Program，and a start-up talent of Chengdu's "Rong Piao Plan". She led several major projects of the 863 Program and multiple key research projects of the National Science and Technology Department under the "New Drug Development" program during the "11th Five-Year Plan"，"12th Five-Year Plan" and "13th Five-Year Plan". She led the research and development of 10 innovative drugs covering hematological tumors，autoimmune diseases and neurological disorders, among which 8 were approved for clinical trials, 2 entered the critical registration clinical phase III，4 entered the phase II clinical trial，and 3 entered the phase I clinical trial. As the corresponding author or cocorresponding authors, she published over 430 SCI papers in academic journals such as Nature Communications, Science Advances， Clinical Can. Res，and J. Med. Chem. and has been selected as a highly cited scholar in China for five consecutive years，a top 2% global scientist by Stanford University and a scholar with global influence among the top 100,000.